Reaction Details |
| Report a problem with these data |
Target | MAP kinase-activated protein kinase 5 |
---|
Ligand | BDBM50208911 |
---|
Substrate/Competitor | n/a |
---|
Meas. Tech. | ChEMBL_1633321 (CHEMBL3876113) |
---|
IC50 | 10000±n/a nM |
---|
Citation | Katz, JD; Haidle, A; Childers, KK; Zabierek, AA; Jewell, JP; Hou, Y; Altman, MD; Szewczak, A; Chen, D; Harsch, A; Hayashi, M; Warren, L; Hutton, M; Nuthall, H; Su, HP; Munshi, S; Stanton, MG; Davies, IW; Munoz, B; Northrup, A Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors. Bioorg Med Chem Lett27:114-120 (2017) [PubMed] Article |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
MAP kinase-activated protein kinase 5 |
---|
Name: | MAP kinase-activated protein kinase 5 |
Synonyms: | MAP kinase-activated protein kinase 5 (PRAK) | MAPK-Activated Protein Kinase 5 (MK5) | MAPK-activated protein kinase 5 | MAPK5_HUMAN | MAPKAP kinase 5 | MAPKAPK5 | PRAK | p38-regulated/activated protein kinase | p38-regulated/activated protein kinase (PRAK) |
Type: | Serine/threonine-protein kinase |
Mol. Mass.: | 54229.92 |
Organism: | Homo sapiens (Human) |
Description: | Recombinant MAPKAPK5 was phosphorylated by incubation with active p38alpha before assays. |
Residue: | 473 |
Sequence: | MSEESDMDKAIKETSILEEYSINWTQKLGAGISGPVRVCVKKSTQERFALKILLDRPKAR
NEVRLHMMCATHPNIVQIIEVFANSVQFPHESSPRARLLIVMEMMEGGELFHRISQHRHF
TEKQASQVTKQIALALRHCHLLNIAHRDLKPENLLFKDNSLDAPVKLCDFGFAKIDQGDL
MTPQFTPYYVAPQVLEAQRRHQKEKSGIIPTSPTPYTYNKSCDLWSLGVIIYVMLCGYPP
FYSKHHSRTIPKDMRRKIMTGSFEFPEEEWSQISEMAKDVVRKLLKVKPEERLTIEGVLD
HPWLNSTEALDNVLPSAQLMMDKAVVAGIQQAHAEQLANMRIQDLKVSLKPLHSVNNPIL
RKRKLLGTKPKDSVYIHDHENGAEDSNVALEKLRDVIAQCILPQAGKGENEDEKLNEVMQ
EAWKYNRECKLLRDTLQSFSWNGRGFTDKVDRLKLAEIVKQVIEEQTTSHESQ
|
|
|
BDBM50208911 |
---|
n/a |
---|
Name | BDBM50208911 |
Synonyms: | CHEMBL3884319 |
Type | Small organic molecule |
Emp. Form. | C23H22N4O2 |
Mol. Mass. | 386.4464 |
SMILES | CC1(C)C(=O)N([C@H]2CCc3c2cccc3O)c2nc(Nc3ccccc3)ncc12 |r| |
Structure |
|